Active surveillance for prostate cancer compared with immediate treatment: An economic analysis

Cancer

Volumn 118, Issue 14, 2012, Pages 3512-3518

  Keegan, Kirk A ^a   Dall'Era, Marc A ^b   Durbin Johnson, Blythe ^b   Evans, Christopher P ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

active surveillance; cost; economics; Markov model; prostate cancer

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST CONTROL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HEALTH CARE COST; HIDDEN MARKOV MODEL; HUMAN; IMAGE GUIDED RADIOTHERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

BIOPSY; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; MALE; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; WATCHFUL WAITING;

EID: 84862828885     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26688     Document Type: Article

References (23)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61: 212-236.
2. Dall'Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008; 112: 1650-1659. (Pubitemid 351536825)
3. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010; 8: 162-200.
4. Cooperberg MR, Cowan JE, Hilton JF, et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol. 2011; 29: 228-234.
5. Albertsen PC, Moore DF, Shih W, et al. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011; 29: 1335-1341.
6. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J,. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst. 2010; 102: 950-958.
7. Dall'Era MA, Konety BR, Cowan JE, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008; 112: 2664-2670. (Pubitemid 351969209)
8. Krahn MD, Zagorski B, Laporte A, et al. Healthcare costs associated with prostate cancer: estimates from a population-based study. BJU Int. 2010; 105: 338-346.
9. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A,. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010; 28: 126-131.
10. Manoharan M, Eldefrawy A, Katkoori D, Antebi E, Soloway MS,. Comparison of urologist reimbursement for managing patients with low-risk prostate cancer by active surveillance versus total prostatectomy. Prostate Cancer Prostatic Dis. 2010; 13: 307-310.
11. Hayes JH, Ollendorf DA, Pearson SD, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010; 304: 2373-2380.
12. Wilson LS, Tesoro R, Elkin EP, et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer. 2007; 109: 518-527. (Pubitemid 46190959)
13. Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011; 29: 1517-1524.
14. Inadomi JM,. Decision analysis and economic modelling: a primer. Eur J Gastroenterol Hepatol. 2004; 16: 535-542. (Pubitemid 38703861)
15. Cooperberg MR, Carroll PR, Klotz L,. Active surveillance for prostate cancer: progress and promise. J Clin Oncol. 2011; 29: 3669-3676.
16. Cooperberg MR, Broering JM, Carroll PR,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010; 28: 1117-1123.
17. Klotz L,. Active surveillance for prostate cancer: patient selection and management. Curr Oncol. 2010; 17 (suppl 2): S11-S17.
18. Conti SL, Dall'era M, Fradet V,. Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol. 2009; 181: 1628-1633.
19. Tosoian JJ, Trock BJ, Landis P,. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011; 29: 2185-2190.
20. Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007; 178: 2359-2364; discussion 2364-2365.
21. Evans CP,. Follow-up surveillance strategies for genitourinary malignancies. Cancer. 2002; 94: 2892-2905. (Pubitemid 34547688)
22. Corcoran AT, Peele PB, Benoit RM,. Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer. Urology. 2010; 76: 703-707.
23. Zaytoun OM, Vargo EH, Rajan R, et al. Emergence of fluoroquinolone- resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology. 2011; 77: 1035-1041.